NVAX as seen on the weekly chart has been in price distress for a long time.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
up over 100% adding into the trade now.